SCHEMBL23980607

SCHEMBL23980607

COc1cc2c(OC)cccc2cc1C(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 1/20 0.53
HPGD P15428 1/20 0.53
HSD17B10 Q99714 1/20 0.53
NQO1 P15559 1/20 0.46
HDAC4 P56524 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
GFER P55789 1/20 0.42
SOS1 Q07889 5/20 0.40
KRAS P01116 4/20 0.40
ACHE P22303 2/20 0.39
KCNK3 O14649 1/20 0.39
KCNK9 Q9NPC2 1/20 0.39
P2RX3 P56373 1/20 0.38
P2RX2 Q9UBL9 1/20 0.38
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2971769 0.86 POLB (0.47) KDM4EALDH1A1HPGDHSD17B10NQO1
SCHEMBL27851959 0.82 ALDH1A1 (0.50) KDM4EALDH1A1HPGDHSD17B10NQO1
SCHEMBL27851958 0.82 ALDH1A1 (0.57) KDM4EALDH1A1HPGDHSD17B10NQO1
SCHEMBL12767844 0.81 NQO1 (0.52) KDM4EALDH1A1HPGDNQO1POLB
SCHEMBL29919905 0.80 NQO1 (0.67) KDM4EALDH1A1HPGDHSD17B10NQO1
SCHEMBL8393507 0.80 NQO1 (0.67) KDM4EALDH1A1HPGDHSD17B10NQO1
SCHEMBL8391116 0.78 ALDH1A1 (0.59) KDM4EALDH1A1HPGDHSD17B10NQO1
SCHEMBL29862025 0.78 ALDH1A1 (0.59) KDM4EALDH1A1HPGDHSD17B10NQO1
SCHEMBL18134572 0.77 ALDH1A1 (0.48) KDM4EALDH1A1HPGDHSD17B10NQO1
SCHEMBL17789985 0.76 ALDH1A1 (0.43) KDM4EALDH1A1HPGDHSD17B10NQO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167081-A1 5-AMINO-2-PIPERIDINON-3-YL-1-OXOISOINDOLINE DERIVATIVES FOR DEGRADATION OF IKZF2 DEGRADERS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2023-06-01 US disclosed
US-20230167081-A1 5-AMINO-2-PIPERIDINON-3-YL-1-OXOISOINDOLINE DERIVATIVES FOR DEGRADATION OF IKZF2 DEGRADERS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2023-06-01 US disclosed
WO-2021222542-A1 5-AMINO-2-PIPERIDINON-3-YL-1-OXOISOINDOLINE DERIVATIVES FOR DEGRADATION OF IKZF2 DEGRADERS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167081-A1 5-AMINO-2-PIPERIDINON-3-YL-1-OXOISOINDOLINE DERIVATIVES FOR DEGRADATION OF IKZF2 DEGRADERS IKZF1, IKZF3, IKZF2 KDM4E 121/4885ALDH1A1 3240/4885HPGD 3362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.